. 2013 Sep 26:53–74. doi: 10.1007/978-81-322-1029-0_4

Table 4.4.

Features of currently licensed vaccines

Vaccine	Parent strain and genotype	Formulation	Dose	Side effects	Protective efficacy
Rota Teq	Bovine rotavirus strain WC3, P7[5]G6	5 reassortants; 4 reassortants with the VP7 specificity for serotype 1, 2, 3, or 4, and 1 reassortant with the VP4 of P1A[8] specificity from the human rotavirus parent strain with the remainder of the genes from the WC3 bovine rotavirus parent	3 oral doses at 2, 4, and 6 months of age	Intussusceptions not seen. Diarrhea and vomiting may occur	84.7 % against severe gastroenteritis and hospitalization
Rotarix	Human rotavirus strain 89-12, G1 P1A[8]	No reassortants; attenuation by passage of human rotavirus 89-12 strain in tissue culture	2 oral doses at 2 and 4 months of age	Intussusceptions not seen. Diarrhea and vomiting may occur	89 % against all rotavirus disease

Vaccine

Parent strain and genotype

Formulation

Dose

Side effects

Protective efficacy

Rota Teq

Bovine rotavirus strain WC3, P7[5]G6

5 reassortants; 4 reassortants with the VP7 specificity for serotype 1, 2, 3, or 4, and 1 reassortant with the VP4 of P1A[8] specificity from the human rotavirus parent strain with the remainder of the genes from the WC3 bovine rotavirus parent

3 oral doses at 2, 4, and 6 months of age

Intussusceptions not seen. Diarrhea and vomiting may occur

84.7 % against

severe gastroenteritis

and hospitalization

Rotarix

Human rotavirus strain 89-12, G1 P1A[8]

No reassortants; attenuation by passage of human rotavirus 89-12 strain in tissue culture

2 oral doses at 2 and 4 months of age

Intussusceptions not seen. Diarrhea and vomiting may occur

89 % against all rotavirus disease